Renaissance Capital logo

Angion Biomedica Priced, Nasdaq: ANGN

Phase 3 biotech developing small molecule therapies for acute organ injuries.

Industry: Health Care

Latest Trade: $10.69 0.00 (0.0%)

First Day Return: +6.4%

Return from IPO: -33.2%

Industry: Health Care

We are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that we are currently evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart. Within AKI, we are currently evaluating ANG-3777's ability to improve kidney function and reduce the severity of transplant-associated AKI, also known as delayed graft function (DGF), in patients at risk for kidney dysfunction, as well as for the treatment of AKI associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI). We are also evaluating ANG-3777 for indications within acute lung injury (ALI), with our primary focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. We are advancing multiple programs for the treatment of fibrotic diseases, leading with ANG-3070, a tyrosine kinase inhibitor (TKI), and our inhibitor of rho kinase 2 (ROCK2). We also continue to develop other preclinical product candidates, including our CYP11B2 (aldosterone synthase) inhibitors, which we are investigating for the purpose of targeting aldosterone-related fibrotic diseases.
more less
IPO News for Angion Biomedica
more
IPO Data
IPO File Date 01/15/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $80
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/04/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 5.0
Deal Size ($mm) $80
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Uniondale, NY
Founded 1998
Employees 53
Website www.angion.com